MedTrace Logo

Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma

NCT01082809 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2014-05-14

No results posted yet for this study

Summary

The purpose of this study is to determine whether sunitinib as second-line treatment in advanced biliary tract carcinoma

Conditions

  • Advanced Biliary Tract Adenocarcinoma

Interventions

DRUG

Sunitinib

Sunitinib 37.5 mg orally once daily continuously, comprising a 4-week cycle

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Ho yeong Lim, M.D,Ph.D · Samsung Medical Center, Seoul, Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2012-01-31
Completion
2012-02-29

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01082809 on ClinicalTrials.gov